Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Elevance Health Inc. (ELV) has a Wall Street consensus price target of $387.14, based on estimates from 37 covering analysts. With the stock currently trading at $320.00, this represents a potential upside of +21.0%. The company has a market capitalization of $70.63B.
Analyst price targets range from a low of $332.00 to a high of $425.00, representing a 24% spread in expectations. The median target of $394.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 26 analysts rating the stock as a Buy or Strong Buy,11 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ELV trades at a trailing P/E of 12.7x and forward P/E of 12.3x. The forward PEG ratio of 1.78 indicates reasonable valuation for growth. Analysts expect EPS to grow +1.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $427.41, with bear and bull scenarios of $329.43 and $763.62 respectively. Model confidence stands at 79/100, indicating high predictability in the company's fundamentals.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ELV stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for ELV is $387.14, representing 21.0% upside from the current price of $320. With 37 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ELV has a consensus rating of "Buy" based on 37 Wall Street analysts. The rating breakdown is predominantly bullish, with 26 Buy/Strong Buy ratings. The consensus 12-month price target of $387.14 implies 21.0% upside from current levels.
With a forward P/E of 12.3118x, ELV trades at a relatively low valuation. The consensus target of $387.14 implies 21.0% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $425 for ELV, while the most conservative target is $332. The consensus of $387.14 represents the median expectation. Our quantitative valuation model projects a bull case target of $764 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ELV is heavily covered by Wall Street, with 37 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 26 have Buy ratings, 11 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ELV stock forecast based on 37 Wall Street analysts shows a consensus price target of $387.14, with estimates ranging from $332 (bear case) to $425 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $427, with bear/bull scenarios of $329/$764.
Our quantitative valuation model calculates ELV's fair value at $427 (base case), with a bear case of $329 and bull case of $764. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 79/100.
ELV trades at a forward P/E ratio of 12.3x based on next-twelve-months earnings estimates compared to a trailing P/E of 12.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on ELV, with a "Buy" consensus rating and $387.14 price target (21.0% upside). 26 of 37 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ELV analyst price targets range from $332 to $425, a 24% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $387.14 consensus represents the middle ground. Our model's $329-$764 range provides an independent fundamental perspective.